“Clinically important response rates, combined with the low...

“Clinically important response rates, combined with the low adverse event rate observed with this combination, opens the possibility for this CAVATAK with ipilimumab combination to move into a pivotal registration study in patients who have failed prior checkpoint inhibitor therapy.”
Moving forward in right direction, hope new advisory team hard at work designing a trial.